Skyhawk Therapeutics
Skyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's Disease
More than 50,000 doses of SKY-0515 have now been administered to patients. BOSTON, Nov. 5, 2026 — Skyhawk Therapeutics, Inc., a clinical-stage…